Correvio Pharma Corp. announced that seven abstracts featuring Zevtera/Mabelio (ceftobiprole medocaril sodium), an intravenous (IV) cephalosporin antibiotic with rapid bactericidal activity against a wide range of Gram-positive and Gram-negative bacteria, were selected for presentation at the 29th European Congress of Clinical Microbiology and Infectious Disease, being held April 13-16, 2019 in Amsterdam, the Netherlands. Correvio currently markets ceftobiprole under the brand name Mabelio in Italy and France and under the brand name Zevtera in the UK, Germany, Spain, Austria and Switzerland.